Memorial Sloan Kettering Cancer Center

- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.
- Conditions
- Esophageal Carcinoma
- Interventions
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT00590031
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
- Conditions
- CNS CancerIntracranial HemangiopericytomaMeningiomaHemangioblastomaNeurofibromatosis
- Interventions
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00589784
- Locations
- 🇺🇸
University of Virginia Health Science Center, Charlottesville, Virginia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States
Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Other: Blood testOther: Questionnaire
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 383
- Registration Number
- NCT00590109
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Menstrual Cycle Maintenance and Quality of Life: A Prospective Study
- Conditions
- Breast CancerMenstrual CycleAmenorrhea
- Interventions
- Other: Questionnaire
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 810
- Registration Number
- NCT00589654
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene
- Conditions
- Lung CancerNon-small Cell Lung CancerBronchioloalveolar Cancer
- Interventions
- First Posted Date
- 2008-01-08
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT00588445
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Immediate Vaginal Reconstruction After Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function
- Conditions
- Vaginal Cancer
- Interventions
- Behavioral: QOL
- First Posted Date
- 2008-01-08
- Last Posted Date
- 2016-08-10
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00588081
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
- Conditions
- Brain MetastasisBladder CancerBreast CancerColon CancerMelanomaCervical CancerHEENT CancerProstate CancerSarcomaLung Cancer
- Interventions
- Radiation: Stereotactic Radiosurgery
- First Posted Date
- 2008-01-08
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00587964
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
- Conditions
- LymphomaB-cell Non-Hodgkin's Lymphoma
- Interventions
- Drug: Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
- First Posted Date
- 2008-01-08
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT00588094
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
- First Posted Date
- 2008-01-08
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 300
- Registration Number
- NCT00588185
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey, United States
Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer
- First Posted Date
- 2008-01-08
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT00588003
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States